Nordic Nanovector to collaborate with Heidelberg Pharma to develop leukaemia treatment

pharmafile | October 26, 2016 | News story | Research and Development Nordic Nanovector, WILEX, heidelberg pharma, leukaemia 

Nordic Nanovector has announced that they have formed a partnership with WILEX subsidiary, Heidelberg Pharma. Heidelberg Pharma specialises in the development of antibody-drug conjugates (ADCs) and so, together, they will work on developing treatment for leukaemias.

On Nordic Nanovector’s part, it forms a strategy to develop a constant turnover of targeted therapies. With this collaboration, this means being able to expand into antibody products conjugated to anti-cancer compounds that are not radionuclides.

Jostein Dahle, Nordic Nanovector’s chief scientific officer, commented: “We are pleased to further expand our R&D activities into the ADC area with Heidelberg Pharma in this second strategic collaboration, following closely the collaboration announced recently with LegoChem. During the past year, we have made important steps to execute our strategy designed to build a pipeline of innovative antibody-radionuclide conjugates (ARCs) and ADCs that combine our expertise and platform with complementary technologies from expert partners. This strategy is aimed at creating multiple new targeted treatment options for patients who suffer a range of leukaemias and lymphomas.”

Professor Dr Andreas Pahl, head of research & development and member of the management board of WILEX and Heidelberg Pharma, commented: “This project extends our portfolio of ADCs to further haematological cancers. Nordic Nanovector has an established chemistry, manufacturing, and controls (CMC) process for their antibody which will speed up processes and reduce the development costs of an ADC.”

Ben Hargreaves

Related Content


NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be …


NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line …


AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus …

Latest content